Serina Therapeutics shares fell 7% premarket after the FDA placed a clinical hold on its application to begin trials for its Parkinsons therapy candidate, SER-252. The agency requested more data about an excipient used in the drug formulation. Serina clarified that the feedback does not concern the active ingredient or its mechanism of action.